Gyre Therapeutics (GYRE) Non-Current Assets (2010 - 2026)

Gyre Therapeutics (GYRE) has 17 years of Non-Current Assets data on file, last reported at $70.3 million in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $70.3 million, up 14.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $256.2 million (down 1.38% YoY), and the FY2025 annual result was $63.8 million, up 5.18% from the prior year.
• Non-Current Assets improved to $70.3 million in Q1 2026 per GYRE's latest filing, from $63.8 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $70.4 million in Q3 2024 and troughed at $773000.0 in Q3 2022.
• A 5-year average of $40.6 million and a median of $59.3 million in 2023 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2022 and 2024: Non-Current Assets plunged 83.1% in 2022, then jumped 1357.6% in 2024.
• A 5-year view of Non-Current Assets shows it stood at $35.1 million in 2022, then jumped by 69.0% to $59.3 million in 2023, then increased by 2.19% to $60.6 million in 2024, then advanced by 5.18% to $63.8 million in 2025, then advanced by 10.23% to $70.3 million in 2026.
• Business Quant data shows GYRE's Non-Current Assets at $70.3 million in Q1 2026, $63.8 million in Q4 2025, and $60.8 million in Q3 2025.